ART and Adverse Events Part 2
Emerging Insights on Adverse Events During ART and Implications for Treatment: Nephrotoxicity and Long-Acting Injectables

Released: November 16, 2021

Expiration: November 15, 2022

Fidelia Bernice
Fidelia Bernice, PharmD
Aadia I. Rana
Aadia I. Rana, MD

Activity

Progress
1
Course Completed
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.